ATLANTA, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, today announces that Rick Eiswirth, President and Chief Executive Officer, will present a corporate overview at the H. C. Wainwright and Company 22nd Annual Global Virtual Investor Conference on Tuesday September 15, 2020 at 3:30 PM ET. A live and archived presentation will be available on the Alimera website at https://investors.alimerasciences.com/ALIM/events/3819.
About Alimera Sciences, Inc.
Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations. For more information, please visit www.alimerasciences.com.
About Nordic Prime
Nordic Prime is a private owned Danish pharmaceutical distributor, selling to pharmacies and hospitals within the Nordic region. http://www.nordicprime.dk/
Forward Looking Statements
This press release contains “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, Alimera’s expectations with respect to access to ILUVIEN for Nordic hospitals and patients. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in its forward-looking statements. Meaningful factors which could cause actual results to differ include, but are not limited to, Nordic Prime’s ability to launch ILUVIEN in the Nordic countries, Nordic Prime’s ability to successfully obtain tender business for ILUVIEN, the acceptance by physicians in the Nordic countries of ILUVIEN for use with DME and posterior uveitis patients, as well as other factors discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Alimera’s Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020 and June 30, 2020, which are on file with the Securities and Exchange Commission (SEC) and available on the SEC’s website at www.sec.gov.
All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. Alimera cautions investors not to rely too heavily on the forward-looking statements Alimera makes or that are made on its behalf. These forward-looking statements speak only as of the date of this press release (unless another date is indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
|For press inquiries:||For investor inquiries:|
|Jules Abraham||Scott Gordon|
|for Alimera Sciences||for Alimera Sciences|